

Magdalena o.p.s. works with people living with infectious diseases mainly in harm reduction programs and addiction treatment. HR programs are mainly about testing their low-threshold clients in drop-in centres and outreach programs. If the infection is detected, they then mediate the possibility of treatment and support the client throughout the treatment. They test clients for syphilis, hepatitis C, hepatitis B and HIV. In the Czech Republic, there is the highest incidence of hepatitis C among users of addictive substances, so Magdalena o.p.s. focuses mostly on education and prevention, especially in the context of this disease. Hepatitis B is on the decline in the Czech Republic. In the treatment of addiction, they also work with people who have an infectious disease, but they often come to us already diagnosed and with a set treatment. If they come to one of our outpatient clinics for the first contact, infectious diseases are one of the things they ask about. They then offer the possibility of testing. In residential treatments, being tested for infectious diseases is mandatory. Every year Magdalena o.p.s. participates in various events supporting resistance among clients, but also in the majority population. They took a part in European test week, providing hepatitis and HIV testing and they shared posts about testing on their social media networks, etc. They have various projects to increase the resistance rate of the user population and improve the reach of treatment for this population, working closely with the Institute of Clinical and Experimental Medicine in Prague.
Hepatitis and PWID/harm reduction
11:35 – 11:40
Chair: WHO – Intro and set the scene.
11:40 – 11:55
Co-chair: EMCDDA – Monitoring viral hepatitis elimination among PWID in Europe.
11:55 – 12:00
ID 29: Ema Pos (not yet registered)
Title: If the mountain won’t come to Mohammed: lessons from a decentralized Infectious Disease consultation.
12:05 – 12:10
ID 152: Brian Conway (Registered in person)
Title: Community Pop-up Clinic: Cascade of Care and HCV Treatment of Vancouver’s inner-city PWID Populations.
12:10 – 12:15
ID 212: Jasmine West (not yet registered)
Title: From lived experience to lived expertise: a syndemic approach.
12:15 – 12:20
ID: 299 Mercy Nyakowa (Registered in person)
Title: HCV and HBV prevalence and associated risk factors among people who inject drugs (PWIDs) in Kenya
12:20 – 12:25
ID: 133 Nalinikanta Rajkumar (Registered in person)
Title: Rapid regimen of HBV vaccination: Does it work for high risk groups?
12:25 – 12:30
Q&A and closing remarks
tHIS
IS
BEN’S
BIG
TEST
effective case finding strategies
Supported by Vir Biotechnology, Inc
During this session you will hear from hepatitis Delta expert, Dr. Maria Buti, and a patient who has lived with hepatitis Delta in a panel discussion moderated by Dr. Carey Hwang, Chief Medical Officer (interim) of Vir Biotechnology. This panel will inform perspectives on patient needs, opportunities for enhanced screening, and strengthening linkages to care.
Session Agenda
14:40 – 14:45
Panel overview and introductions facilitated by Dr Carey Hwang (Vir Biotechnology)
14:45 – 15:05
Panel discussion: Dr Maria Buti (University Hospital Vall d’Hebron, Spain), Milanka Barbosa, Dr Carey Hwang (Chief Medical Officer interim), Vir Biotechnology
15:05 – 15:10
Final remarks and close